No headlines found.
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 12-May 4:05 PM ET)
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics trades on the NASDAQ stock market under the symbol BOLT.
As of June 5, 2026, BOLT stock price declined to $4.56 with 10,975 million shares trading.
BOLT has a beta of 1.16, meaning it tends to be more sensitive to market movements. BOLT has a correlation of 0.06 to the broad based SPY ETF.
BOLT has a market cap of $8.76 million. This is considered a Sub-Micro Cap stock.
Last quarter Bolt Biotherapeutics reported $26,000 in Revenue and -$4.31 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.86.
In the last 3 years, BOLT traded as high as $34.20 and as low as $3.91.
The top ETF exchange traded funds that BOLT belongs to (by Net Assets): VXF.
BOLT has underperformed the market in the last year with a price return of -23.5% while the SPY ETF gained +25.6%. BOLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +4.8% and -7.9%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
BOLT support price is $4.41 and resistance is $5.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BOLT shares will trade within this expected range on the day.